University of Zurich

BOSTON, MA / ZURICH, SWITZERLAND / ACCESSWIRE / December 20, 2024 / The Swiss MedTech startup ZuriMED Technologies AG is pleased to announce FDA clearance of its FiberLocker® System, a cutting-edge solution for rotator cuff repair reinforcement. This milestone marks the upcoming U.S. launch in early 2025 and enables surgeons to leverage this novel technology for rotator cuff repair procedures.Just in time for the holiday season, ZuriMED Technologies AG celebrated a significant achievement: FDA clearance of their 510(k) submission for the FiberLocker® System. This represents the first clinical indication of the pioneering Surgical-Fiberlock® technology.Rotator cuff tears are among the most prevalent shoulder-related ailments, affecting a vast segment of the population.1 Traditional repair techniques often fail at the suture-tendon interface2, leading to retears that necessitate further surgeries and extend recovery times. Committed to resolving this critical issue, ZuriMED has introduced the FiberLocker® System. This novel technology reinforces soft tissue repairs at the time of surgery in an effort to improve traditional repair techniques.3The FiberLocker® System: Felting is the SolutionThe FDA-cleared medical device comprises two components: A patch (SpeedPatch® PET), which is implanted onto the repaired tendon, and a single-use instrument (FiberLocker® Instrument SN), designed to facilitate its fixation. Hereby, the startup has been translating an established technology from the textile industry into medicine - felting.Made of non-woven polyethylene terephthalate (PET) fibers, the patch acts as medical felt. During surgery, the FiberLocker® Instrument SN employs a reciprocating needle that pushes the fibers into the underlying tendon tissue, creating an interwoven construct that securely integrates the implant to the tendon.Unlike other augmentation methods, the FiberLocker® System simplifies the fixation process and establishes a new method for soft tissue repair by offering immediate, enhanced biomechanical support.2 "I truly believe that ZuriMED's unique technology has the potential to become a game changer in shoulder surgery by helping us to improve patient's outcomes. The application of the device is simple and fast and has shown to reinforce traditional repair techniques," said Prof. Dr. Karl Wieser, Head of Shoulder and Elbow Surgery at Balgrist University Hospital.Pre-Clinical Data: A Robust Foundation for FDA ClearanceComprehensive ex vivo biomechanical testing has supported the enhanced suture retention and even load distribution across the implant achieved with the FiberLocker® System.3 The technology facilitates an arthroscopic procedure, streamlining the surgical process with a rapid, 90-second patch-to-tendon fixation.3Further supporting its clinical utility, in vivo animal studies have confirmed the excellent biocompatibility of the SpeedPatch® PET, with no adverse effects noted up to 13 weeks post-implantation. The implant was well-tolerated and integrated with the tendon, evidenced by a smooth transition between the patch and tendon tissues and cellular ingrowth into the porous scaffold.3,4Mission Statement: Innovation Rooted in Zurich‘s Health ClusterThe FiberLocker® System is the fruit of five years of dedicated effort by the team at ZuriMED Technologies AG, situated within Zurich's premier health care cluster and supported by the Balgrist Beteiligungs AG. Originating from the Laboratory of Orthopedic Biomechanics at ETH Zurich and the University of Zurich, the startup has capitalized on direct access to leading-edge research labs at Balgrist Campus and top-tier orthopedic clinics like Balgrist University Hospital. These collaborations have accelerated the system's journey from concept to clinical application, showcasing a swift bench-to-bedside transition.Professor Jess Snedeker, a professor of orthopedic biomechanics and co-founder of ZuriMED Technologies along with Dr. Xiang Li and Elias Bachmann, had this to say: "The challenges of traditional rotator cuff repair, long a source of frustration for both patients and surgeons, are intended to be addressed with our FiberLocker® System. This FDA clearance isn't just a milestone for ZuriMED - it represents a significant leap forward in surgical technology. Our system, born from pioneering research and clinical collaborations, has the potential to enhance patient outcomes. With the U.S. launch on the near horizon, we are poised to set new benchmarks in soft tissue repair."With the recent clearance of the FiberLocker® System, ZuriMED is driven by the ambition to leave a long-lasting impact on the medical technology landscape. The company anticipates a limited U.S. market release of the SpeedPatch® PET and FiberLocker® Instrument SN in early 2025, allowing patients to soon benefit from this new technology.1 Zumstein MA, Künzler M, Hatta T, Galatz LM, Itoi E. Rotator cuff pathology: state of the art. Journal of ISAKOS. 2017 July, 213-2212 Cummins CA, Murrell GA. Mode of failure for rotator cuff repair with suture anchors identified at revision surgery. J Shoulder Elbow Surg. 2003 Mar-Apr, 128-333 Meyer DC, Bachmann E, Darwiche S, Moehl A, von Rechenberg B, Gerber C, Snedeker JG. Rotator Cuff Repair and Overlay Augmentation by Direct Interlocking of a Nonwoven Polyethylene Terephthalate Patch Into the Tendon: Evaluation in an Ovine Model. Am J Sports Med. 2023 Oct, 3235-3242.4 Data on FileContact information:Name: Alicia WirzEmail: [email protected]Phone Number: +41 44 552 12 28SOURCE: ZuriMED Technologies AGRelated Documents:

A liver transplant, also known as a hepatic transplant, is a surgical procedure that is performed when a patient's liver is not capable of performing basic functions, such as synthesizing proteins, carbohydrates, and fats. After the kidney, the liver is the second most frequently transplanted major organ, indicating the seriousness of the liver disease. Despite the fact that the majority of liver transplant operations use livers from deceased donors, it is still possible to obtain a liver from a living person as well (allograft). Current liver transplant demand is substantial, however only critically ill patients are considered for transplants, and these patients are selected based on their critical condition. NEWARK, DE / ACCESSWIRE / December 3, 2024 / The Liver Transplantation Market 2023 to 2033 is witnessing significant growth, reflecting advancements in medical technology and rising prevalence of liver-related diseases. In 2023, the market is valued at USD 1,409.8 million and is projected to reach USD 2,653.4 million by 2033, marking a robust CAGR of 6.5% over the forecast period.The increasing incidence of liver disorders such as cirrhosis and hepatocellular carcinoma is a major driver. According to WHO, nearly 2 million deaths annually are attributed to liver diseases globally. This has spurred a demand for innovative transplantation techniques and improved donor-recipient matching systems.Government and private sector investments in healthcare infrastructure and organ transplantation programs are creating lucrative opportunities. Additionally, the emergence of minimally invasive techniques and the integration of AI-based tools in organ matching and post-operative care have revolutionized the liver transplantation landscape.As the market expands, Asia-Pacific and North America are expected to dominate due to increased healthcare spending and better awareness programs, while advancements in biotechnology continue to drive the innovation curve.What Factors are Driving Growth of the Liver Transplantation Market?As hepatitis A, B, and C incidence increases worldwide, the liver transplantation market is expected to grow in the coming years. A major driving force in the liver transplantation market is the advancement of treatment and the increase in adoption as the most effective method of managing end-stage liver disease.Additionally, reimbursement policies are likely to become increasingly favorable in the near future, leading to a growth in liver transplantation. The fact that organ transplantation is becoming an increasingly popular treatment for organ failure is one of the most significant factors contributing to the growth of the market.During the coming years, the market will experience a great deal of growth due to the rise of passive lifestyles, bad eating habits, excessive drinking, and drug abuse being among the main factors that are driving the market to grow. Various causes of liver failure among the global population as well as the growing geriatric population have increased the demand for liver transplants in various regionsRequest a Sample Copy of This Report Now: https://www.fmisamplereport.com/sample/rep-gb-1281Key Takeaways from Market StudyMarket Size in 2023: USD 1,409.8 millionMarket Size in 2033: USD 2,653.4 millionCAGR (2023-2033): 6.5%Key Growth Regions: North America, Asia-Pacific"The liver transplantation market is entering a dynamic growth phase with the integration of cutting-edge technologies such as AI and robotic surgeries. While the increasing burden of liver diseases presents challenges, the market's rapid adaptation to patient needs and regulatory frameworks ensures a promising future. Public-private collaborations will play a pivotal role in accelerating accessibility and affordability." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)Restricting Factors for the Global Liver Transplantation Market?There are several risks associated with this procedure, including severe bleeding and negative reactions that can be life-threatening, which is a restraint on its use. Several other diseases that can occur as a result of transplants, such as diabetes, high cholesterol, and diarrhea, may impact the market's growth. Staying in a hospital for a long period of time can be expensive, which can hamper the growth of the liver transplantation market.In addition, there are several factors that contributed to the sharp decline in the market's revenue not only in recent years, but also in the future, including the shortage of primary intensive care units, protective equipment, and blood products during transplantation. Over the forecast period, however, liver transplantation market growth can be hindered by a shortage of liver donors, increased waiting lists for liver transplants, and an increase in hospitalization time and costs. As a result, liver transplantation will see a decline in market share in the near future. Component InsightsThe liver transplantation market comprises key components such as immunosuppressive drugs, surgical equipment, and post-operative care services. Among these, immunosuppressive drugs hold the largest share due to their essential role in preventing graft rejection.Growth DriversAdvanced Surgical Techniques: Minimally invasive procedures reduce patient recovery times and risks.Rising Awareness: Growing public understanding of liver health and the importance of transplantation.Supportive Regulations: Policies facilitating faster approvals of new portable medical devices and drugs.Emerging Innovators Are Leading a Transformation in Liver TransplantationA new wave of innovative start-ups, particularly in Western markets, is reshaping the liver transplantation landscape. These companies are introducing cutting-edge medical devices aimed at streamlining transplant procedures, ultimately offering significant benefits to both donors and recipients.Several European firms are pioneering advancements in the preservation of livers donated by both living and deceased individuals. Traditionally, the usable window for a liver after removal from the body is just 12 hours, beyond which the organ is no longer viable for transplantation. Efforts are underway to extend this critical time frame, providing more flexibility and improving patient outcomes.HepaTx, a U.S.-based company, is making strides in the field of regenerative medicine. They are developing stem cell-based therapies as alternatives to liver transplants, targeting patients with late-stage liver diseases. According to their data, only one in thirty-three patients in need of a liver transplant receives an organ in time, highlighting the ongoing challenges in the donor-recipient imbalance despite significant government investments in healthcare.Recent Advancements in Liver TransplantationA ground breaking procedure took place in September 2023 at Jaslok Hospital and Research Center in Mumbai, where a single liver was used to save two lives through a split cadaver liver donation surgery. This method divides the liver into two parts, enabling both an adult and a pediatric patient to benefit from the transplant simultaneously.In another notable development, the Liver4Life team at the University of Zurich has created an innovative blood perfusion machine. This device has the potential to extend the preservation time of a liver to 72 hours, a significant improvement over the previous 12-15 hours. The normothermic perfusion machine mimics the function of a human body by pumping blood to the liver, while supplying essential nutrients and medications to keep the organ in optimal condition before transplantation. This breakthrough has the potential to dramatically improve the viability of donor livers, making a substantial impact on the field.In-Depth Market Analysis: A Complete Reporthttps://www.futuremarketinsights.com/reports/liver-transplantation-marketKey Market PlayersAllosourceConatus Pharmaceuticals Inc.Digna Biotech S.L.Dompe Farmaceutici S.p.A.Isogenis, Inc.RedHill Biopharma Ltd.Thompson SurgicalIntegra Life SciencesBaxter International Inc.XVIVOVirTech BioVital TherapiesHepaTxHumedicsRegional Analysis of Liver Transplantation MarketNorth America: Largest market share with advanced healthcare infrastructure.Europe: Strong government support and rising organ donation rates.Asia-Pacific: Fastest growth driven by increasing medical tourism and awareness.Middle East & Africa: Emerging market due to improved healthcare facilities.Key Segments Profiled in the Global Liver Transplantation MarketBy Treatment Type:Liver Transplantation SurgeryPost-Surgery Anti-Rejection TreatmentCyclosporineTacrolimusSirolimus Prednisone AzathioprineMycophenolate MofetilBy End Use:HospitalsAdult Liver Transplantation CentersAmbulatory Surgical CentersBy Region:North AmericaLatin AmericaEuropeAsia PacificThe Middle East and AfricaAuthorSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Extensive Coverage in the Healthcare Domain:The global liver fibrosis treatment market is expected to surpass an impressive valuation of USD 16.43 billion in 2023 and is projected to exhibit a CAGR of 11% from 2023 to 2033.The injectable drug delivery market is, according to industry analysis, estimated to be around a staggering USD 49.44 billion, as of 2024.The global drug delivery technology market is expected to be valued at USD 43.9 billion in 2023.The global hematopoietic stem cell transplantation market garnered a market value of USD 7 Billion in 2023The cross-species organ transplantation market is projected to be valued at USD 14.8 billion by 2024 and rise to USD 30.5 billion by 2034.The global medical cannula market size is forecast to reach USD 445 Million in 2022.The global medical robot market growth is poised to garner a 12.9% CAGR through 2034.The United States digital ovulation test kits market size is projected to be valued at USD 77.4 million in 2023 and is expected to rise to USD 185.0 million by 2033.The Cardiac Biomarker Diagnostic Test Kits Market size is projected to be worth USD 1,950 million in 2023.The global digital psychotherapeutics market size is projected to be worth US$ 1.06 billion in 2023. Over the next ten years, global digital psychotherapeutics demand is likely to accelerate at 27.6% CAGR.Trending TopicGlobal Skin Substitutes Market Analysis (2024-2034)About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact UsFuture Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website: https://www.futuremarketinsights.comLinkedIn | Twitter | Blogs | YouTubeSOURCE: Future Market Insights, Inc.

Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research and max EUR 6,000 for 93 young researchers for doctoral dissertation work. Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research. In the last few years the Research Foundation has been distributing annual grants based on applications for the total sum of MEUR 1 for research in medicine, veterinary medicine, pharmacy and related sciences, such as chemistry and physics. Grants for 2025 Grants for postdoctoral research, EUR 25,000 – 50,000 Aatsinki Anna-Katariina, LT, Turun yliopisto, Toiminnalliset vatsavaivat ja suolistomikrobiston kehitys lapsuudessa, EUR 25,000 Acosta Manzano Francisco Miguel, Researcher, Turun yliopisto, Medicity (University of Turku) and Turku PET Centre (Turku University Hospital), Unlocking the Power of Brown Fat: New Targets in the Fight Against Cardiometabolic Disease, EUR 50,000 Awad Shady, M.D., Ph.D., University of Oxford, Oxford, UK, Identification of Molecular Vulnerabilities Role in TP53-mutant Leukemic Evolution of Myeloproliferative Neoplasms, EUR 25,000 Carpén Timo Pertti Mikael, LKT, dosentti, erikoislääkäri, palliatiivinen erityispätevyys, Helsingin yliopisto, Virtual symptom screening with Targeted Early Palliative care (STEP2) versus usual care for patients with advanced cancer: a randomized controlled trial., EUR 40,000 Göös Helka Linnea, FT, Suomen Punainen Risti, Veripalvelu, Enhancing CAR-NK cell effectiveness using base editing, EUR 25,000 € Häkli Martta Ida Emilia, Tekniikan tohtori, Center for iPS Cell Research and Application, Kyoto University, Hypertrofinen kardiomyopatia kantasolupohjaisissa sydänorganoideissa, EUR 30,000 Kim Daehong, Postdoc Fellow, University of Zurich, University of Helsinki, Unravelling gastrointestinal graft-versus-host disease: Organoid transplantation and advanced immune profiling in preclinical models, EUR 25,000 € Korvenlaita Nea Karoliina, Farmasian tohtori, Johns Hopkins School of Medicine, Department of Molecular & Comparative Pathobiology, Baltimore, USA, Aivosairauksien diagnostiikkaa uusin menetelmin: Solunulkoisista vesikkeleistä parempia biomarkkereita, EUR 50,000 Kositsky Adam, FT, Itä-Suomen yliopisto Kuopion kampus, Piezo1 for Tendon: Understanding Biomechanical and Bioregenerative Effects (PiezTUBBE), EUR 30,000 Koskinen Maija-Kreetta, Filosofian tohtori, Helsingin yliopisto, Sleep well and keep calm: Neural mechanisms of sleep disruption-induced anxiety, EUR 25,000 Laivuori Silja Mirjami, Lääketieteen tohtori, Helsingin yliopisto, Peripheral arterial disease in women., EUR 25,000 Lautaoja-Kivipelto Juulia Helene, Liikuntatieteiden tohtori, Oulun yliopisto, The effects of exercise on adipose tissue mitochondrial function and NAD+ metabolism, EUR 30,000 Muroke Valtteri, LT, Helsingin yliopisto, Helsingin Yliopistollinen Keskussairaala, Inflammation and coronary artery disease - Effects of colchicine on proteomic and metabolomic biomarkers in the COLCOT trial, EUR 40,000 Mäkitaipale Heidi Johanna, ELT, pieneläinsairauksien erikoiseläinlääkäri, Helsingin yliopisto, Kaniinien suun mikrobiomi ja sen yhteys krooniseen hammassairauteen, EUR 30,000 Parvanian Sepideh, PhD, MBA, Åbo Akademi, Cell biology department, Contrasting immunogenic and non-immunogenic bladder tumors: immune microenvironment, metabolic influences, and therapeutic resistance, EUR 25,000 Rajamaki Blair, Researcher, Itä-Suomen yliopisto Kuopion kampus, Temporal changes to comorbidity clusters in people with type 2 diabetes in Finland and Australia, EUR 25,000 Savukoski Susanna Marianne, Lääketieteen tohtori, Oulun yliopisto, Hormonikorvaushoidon pitkäaikaiset terveysvaikutukset ennenaikaisesti vaihdevuosiin tulleilla naisilla, EUR 40,000 Urpa Lea Martta, Researcher, Helsingin yliopisto, Understanding the relationship between disordered sleep and autism symptomatology, EUR 40,000 Yrjölä Pauliina Anna Henriikka, Tekniikan tohtori, sairaalafyysikko, Helsingin yliopisto, Biomarkers of adverse structural-functional development in preterm infants, EUR 30,000 Orion Reaserch Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research. These grants are in total EUR 610,000. Grants for doctoral dissertation work, EUR 3,000 – 6,000 In addition, Orion Research Foundation has awarded EUR 3,000 – 6,000 for 93 researchers for doctoral dissertation work. These grants are in total EUR 499,000. Orion Research Foundation sr More info: Siiri Lehtinen Head of Orion Research FoundationTel: +358 (0)10 426 4409siiri.lehtinen(at)orion.fi PublisherOrion Research Foundation sr Attachment List of grant recipients 2025